Shanghai Henlius Biotech, Inc. Stock price

Equities

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:23 2024-03-19 am EDT 5-day change 1st Jan Change
14.4 HKD -3.74% Intraday chart for Shanghai Henlius Biotech, Inc. -1.50% +3.60%

Financials

Sales 2023 * 5.08B 705M 5.51B Sales 2024 * 5.84B 812M 6.35B Capitalization 7.48B 1.04B 8.13B
Net income 2023 * 466M 64.74M 506M Net income 2024 * 569M 79.04M 618M EV / Sales 2023 * 1.47 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 1.28 x
P/E ratio 2023 *
16 x
P/E ratio 2024 *
13.1 x
Employees 3,406
Yield 2023 *
-
Yield 2024 *
-
Free-Float 21.57%
More Fundamentals * Assessed data
Dynamic Chart
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug MT
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection CI
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials MT
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration CI
Shanghai Henlius Biotech Expects Record Full-Year Profit MT
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration CI
Henlius Biotech Completes Phase 1 Clinical Study of Denosumab Biosimilar MT
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed CI
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene CI
Henlius Biotech Renews Promotional Services Deal With Jiangsu Fosun Pharmaceutical Sales for the Marketing of Breast Cancer Drug MT
Indonesia Grants Marketing Approval to Henlius Biotech's Small-Cell Lung Cancer Treatment MT
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration CI
Henlius Biotech Doses First Subject in Phase 1 Trial of Ipilimumab Biosimilar MT
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection) CI
More news
1 day-3.74%
1 week-1.50%
Current month+7.30%
1 month+12.85%
3 months+17.07%
6 months+28.34%
Current year+3.60%
More quotes
1 week
14.14
Extreme 14.14
15.58
1 month
12.44
Extreme 12.44
15.58
Current year
12.20
Extreme 12.2
15.58
1 year
9.60
Extreme 9.6
17.40
3 years
9.60
Extreme 9.6
46.45
5 years
9.60
Extreme 9.6
67.05
10 years
9.60
Extreme 9.6
67.05
More quotes
Managers TitleAgeSince
Founder - 09-11-30
Chief Executive Officer 46 21-11-29
President 56 20-09-30
Members of the board TitleAgeSince
Director/Board Member 51 13-01-14
Director/Board Member 53 18-12-23
Director/Board Member 54 15-06-11
More insiders
Date Price Change Volume
24-03-19 14.4 -3.74% 94 800
24-03-18 14.96 -0.40% 94,615
24-03-15 15.02 +0.94% 301,300
24-03-14 14.88 -0.27% 379,200
24-03-13 14.92 +2.05% 137,200

Delayed Quote Hong Kong S.E., March 19, 2024 at 04:08 am EDT

More quotes
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.77 CNY
Average target price
16.15 CNY
Spread / Average Target
+17.29%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Shanghai Henlius Biotech, Inc. - Hong Kong S.E.